EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Min Xiao iD, Tian Dou iD, Jia Ji iD, Caihua Zhu iD, Yuan Yuan iD, Hongmin Zhou iD, Fangqiong Li iD, Guang Li iD, Shuang Li iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70278 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Min Xiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase 1 Clinical Trial Research Unit, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, People's Republic of China. Hauptthemen laut MEDLINE: Carnosine, Fasting, Organometallic Compounds. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study aimed to demonstrate bioequivalence between generic and original polaprezinc granules by comparing pharmacokinetic (PK) profiles in healthy Chinese subjects under fasting and fed conditions. This PK investigation was conducted with two independent, randomized, open‐label, single‐dose, two‐period, cross‐over studies. Healthy Chinese fasting ( N = 24, 75 mg) or fed ( N = 24, 300 mg) subjects randomly received a single oral dose of the test or reference polaprezinc granules at each period. Blood samples were collected pre‐ and post‐dose for up to 12 h. Blood zinc was determined using a validated ICP‐MS method. Primary PK endpoints were calculated using non‐compartmental methods, including peak concentration ( C max ) and the areas under the plasma concentration‐time curve (AUC 0–t , AUC 0–∞ ). The geometric mean ratios (GMR) in primary PK endpoints between the test and reference products with 90% confidence intervals (CI) were calculated. Treatment‐emergent adverse events were assessed. In the fasting study, C max , AUC 0–t and AUC 0–∞ were 1.30 ± 0.30 μg/mL, 4.06 ± 1.13 h·μg/mL, and 4.43 ± 1.04 h·μg/mL following 75 mg test product. In the fed study, C max , AUC 0–t and AUC 0–∞ were 0.91 ± 0.26 μg/mL, 3.26 ± 1.06 h·μg/mL, and 3.37 ± 1.07 h·μg/mL following 300 mg test product. The reference product had comparable PK profiles. All 90% CIs of GMRs in C max , AUC 0–t and AUC 0–∞ between the two products were within 80.0%–125.0%. Both study products were well‐tolerated with no serious adverse events. The generic and original polaprezinc granules were bioequivalent by pharmacokinetic comparisons in healthy Chinese subjects under fasting and fed conditions. The two polaprezinc formulations were well‐tolerated with no new safety signals. Trial Registration: CTR20210011

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnosineFastingOrganometallic CompoundsAdolescentAdultFemaleHumansMaleYoung AdultAdministration, OralArea Under CurveChinaCross-Over StudiesDrugs, GenericHealthy VolunteersTherapeutic EquivalencyZincZinc Compounds

Stichwörter der Autor:innen

bioequivalencepharmacokineticspolaprezinc granulessafetytolerability

Substanzen

CarnosineDrugs, GenericOrganometallic CompoundspolaprezincZincZinc Compounds

Autor:innen und Institutionen

  • Phase 1 Clinical Trial Research Unit, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, People's Republic of China.
  • Department of Pharmacy, Huai'an Chuzhou Hospital of Traditional Chinese Medicine, Huai'an, Jiangsu, People's Republic of China.
  • Department of Clinical Medicine, Haisco Pharmaceutical Group co., Ltd., Chengdu, Sichuan, People's Republic of China.

ORCID-Profile: Min Xiao, Tian Dou, Jia Ji, Caihua Zhu, Yuan Yuan, Hongmin Zhou, Fangqiong Li, Guang Li, Shuang Li

Zitieren

APA

Xiao, M., Dou, T., Ji, J., Zhu, C., Yuan, Y., Zhou, H., Li, F., Li, G., & Li, S. (2025). Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical and Translational Science. https://doi.org/10.1111/cts.70278

Vancouver

Xiao M, Dou T, Ji J, Zhu C, Yuan Y, Zhou H, et al. Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical and Translational Science. 2025. doi:10.1111/cts.70278

BibTeX
@article{Xiao2025,
  author = {Xiao, Min and Dou, Tian and Ji, Jia and Zhu, Caihua and Yuan, Yuan and Zhou, Hongmin and Li, Fangqiong and Li, Guang and Li, Shuang},
  title = {Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70278}
}
Kostenlos starten →